Browse grants
Federal opportunities with plain-English eligibility summaries. We aggregate public records — always verify the details on the funder’s site before applying.
Biological Technologies
Due Sep 30, 2026DARPA - Biological Technologies Office · Amount varies
The Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO) is soliciting proposals that leverage biological properties and processes to revolutionize our ability to protect the nation’s warfighters. Specifically excluded is research that primarily results in evolutionary improvements to the existing state of practice.
DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award
Due Sep 30, 2026Defense Health Agency Contracting Activity - DHACA · Amount varies
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award (PCTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of amyotrophic lateral sclerosis (ALS). Projects may range from phase 1 to small-scale phase 2 trials. Applications must address one of the following focus areas: · Biomarker-Driven Interventions: Disease-modifying interventions, with mechanism-specific biomarkers to predict which clinical trial participants are likely to respond, demonstrate target engagement, and effects on the intended biological pathway. · Clinical Care: Improving aspects of clinical care and symptom management for ALS. Distinctive Features: Funding from this award mechanism must support a clinical trial. The clinical trial should begin no later than 12 months after the award date or 18 months for U.S. Food and Drug Administration (FDA)-regulated studies. Projects proposing a therapeutic intervention (drug, biologic, and/or device) must incorporate biomarkers specific to the intervention into the trial design. All pre-applications and applications are required to incorporate community collaboration, as described in Section 3.2.2, to optimize research impact. Applications must include a detailed Regulatory Strategy plan that outlines the approach for obtaining regulatory approvals, if required, specifically for the funded portion of the study. In addition, applications must provide a separate Transition Plan that describes how the outcomes of the study will be advanced to the next phase of development, beyond the scope of the funded work.
DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award
Due Sep 30, 2026Defense Health Agency Contracting Activity - DHACA · Amount varies
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients. Distinctive Features: To meet the intent of the funding opportunity, applications may address clinical biomarkers and/or clinical outcomes . This may include the identification, development, and/or validation of promising biomarkers for ALS, which may include, but are not limited to susceptibility/risk, diagnostic, monitoring/disease progression, prognostic, predictive, response, or safety biomarkers. Clinical Outcomes projects may focus on the identification, development, and/or validation of clinician-, observer-, or patient-reported, and/or performance outcome measures for ALS. Projects may include the optimization of current outcome measures already in use. Applications may utilize digital health measures, including wearable devices, smart-phone sensors, video or voice recordings, imaging studies, or other devices which record disease-relevant physiological data and/or outcomes. Community Collaboration is an important element of the FY26 ALSRP COBA. Applicants will be expected to articulate how the proposed research question or study design was informed by the ALS lived experience community.
COE for Technical Training and Human Performance
Due Sep 30, 2026FAA-COE-TTHP · $1–$1M
COE for Technical Training and Human Performance
DoW Breast Cancer, Transformative Breast Cancer Consortium Award
Due Sep 30, 2026Defense Health Agency Contracting Activity - DHACA · Amount varies
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Award supports collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer. Applications must propose a synergistic, highly integrated, multidisciplinary and multi-institutional consortium of leading scientists, clinicians and breast cancer consumer advocates that will address a major problem in a way that a single investigator or group could not accomplish. The consortium’s collaborative efforts must make a transformative impact in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. If the application addresses a different fundamental issue, the application must couple it with at least one of the overarching challenges. Distinctive Features: This funding mechanism allows for up to five Principal Investigators (PIs) which includes the Consortium Director and three or four Project Team PIs. Applications must include at least one breast cancer consumer advocate per project team. Only the Consortium Director will submit a pre-application, but all PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Consortium Director and Project Team PIs) applications by the full application deadline may result in administrative withdrawal.
Center of Excellence for Alternative Jet Fuels and Environment
Due Sep 30, 2026FAA-COE-AJFE · $1–$20M
The opportunity for the Federal Aviation Administration (FAA) Center of Excellence for Alternative Jet Fuel and Environment (AJFE) was awarded in 2013 to the ASCENT cooperative aviation research organization. ASCENT is a coalition of 16 leading US research universities committed to improving the understanding of aviation noise and emissions and the modeling of aviation systems. ASCENT is co-led by Washington State University and the Massachusetts Institute of Technology (https://ascent.aero/). Any new grant opportunities under AJFE are open and available only to the university members of ASCENT.”
DoW Breast Cancer, Breakthrough Award Level 4
Due Sep 30, 2026Defense Health Agency Contracting Activity - DHACA · Amount varies
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Applications must address the challenge in a way that can lead to a breakthrough and have major impact. The FY26 Breakthrough Award mechanism contains four different funding levels designed to support major (but not all) stages of research that will lead to clinical application. Each level specifies a distinct research scope. This program announcement discusses the Breakthrough Award Level 4. Distinctive Features: · Clinical trials are required. · The research team must include two or more breast cancer consumer advocates. · This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.
WINDOWS ON THE UNIVERSE: THE ERA OF MULTI-MESSENGER ASTROPHYSICS
Due Sep 30, 2026U.S. National Science Foundation · Amount varies
The Universe is the ultimate laboratory, and we can now probe it as never before through several powerful and diverse windows – electromagnetic waves, high-energy particles, and gravitational waves. Each of these windows provides a different view. Together they reveal a detailed picture of the Universe that will allow us to study matter, energy, and the cosmos in fundamentally new ways. The “Windows on the Universe” Multi-Messenger Astrophysics (WoU-MMA) program identifies three categories of messengers - electromagnetic waves, high-energy particles including neutrinos and cosmic rays, and gravitational waves. The goals of WoU-MMA are to build the capabilities and accelerate the synergy between observations and theory to realize integrated, multi-messenger astrophysical explorations of the Universe. The WoU-MMA program welcomes proposals in any area of research supported through the participating divisions that address at least one of the following criteria: Coordination: Activities to coordinate observations involving more than one messenger. Observations: Observations of astrophysical objects or phenomena that are potentially sources of more than one messenger. Interpretation: Theory, experiment, simulations and other activities to understand or interpret observations of astrophysical objects that are sources of more than onemessenger. Competitive proposals will accelerate the progress in multi-messenger astrophysics and advance the community activities that have been developed during the initial five-year period of the WoU-MMA program. These build on observational and analysis capabilities at the intersection of the explorations enabled by each of the three windows. Efforts to integrate research communities to develop full interoperability between the three windows, and to develop a skilled new workforce in this field, are also encouraged. Proposals should be submitted to the relevant programs listed below (see Related Programs). The WoU-MMA program is not intended to replace existing programs that make awards that involve experimental or theoretical efforts related to each of the three messengers. Rather, the WoU-MMA program is meant to fund awards that have significant components of multi-messenger astrophysics. Priority will be given to proposals for dedicated efforts that significantly advance the WoU-MMA goals. A proposal that is requesting consideration within the context of WoU-MMA should begin the title with the identifying acronym "WoU-MMA:". PIs should ask for consideration and review as a WoU-MMA proposal only if the proposal addresses at least one of the criteria listed above. Proposals marked for consideration by the WoU-MMA program that do not address at least one of these criteria will be reviewed solely within the participating program(s) to which they were submitted. Supplement requests to existing awards within a program that address one of the above criteria will also be considered.
DoW Breast Cancer, Breakthrough Award Level 3
Due Sep 30, 2026Defense Health Agency Contracting Activity - DHACA · Amount varies
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Applications must address the challenge in a way that can lead to a breakthrough and have major impact. The FY26 Breakthrough Award mechanism contains four different funding levels designed to support major (but not all) stages of research that will lead to clinical application. Each level specifies a distinct research scope. This program announcement discusses the Breakthrough Award Level 3. Distinctive Features: · For this funding mechanism, small-scale clinical trials are allowed but not required. Applications proposing projects with a clinical trial should be submitted under the Clinical Trial option. · The research team must include two or more breast cancer consumer advocates. · This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.
Analysis
Due Sep 30, 2026U.S. National Science Foundation · Amount varies
The Analysis Program supports research in analysis. Areas of current activity include complex, harmonic, and real analysis; dynamical systems and ergodic theory; functional analysis; mathematical physics; operator theory and operator algebras; partial differential equations and calculus of variations. Conferences Proposals to the Analysis Program for conferences or workshops must be submitted through the program solicitation "Conferences and Workshops in the Mathematical Sciences" (link below). Principal Investigators should carefully read the solicitation to obtain important information regarding the substance of proposals for conferences, workshops, and similar activities. To facilitate timely notification of the availability of support, proposals for conferences, workshops, and similar activities should be submitted 8 months in advance of the start date of the proposed event.
FY 2026 Continuation of Solicitation for the Office of Science Financial Assistance Program
Due Sep 30, 2026Office of Science · $50K–$5M
The Office of Science (SC) of the Department of Energy (DOE) hereby announces its continuing interest in receiving applications for support of work in the following program areas: Advanced Scientific Computing Research, Basic Energy Sciences, Biological and Environmental Research, Fusion Energy Sciences, High Energy Physics, Nuclear Physics, and Isotope R&D and Production. On September 3, 1992, DOE published in the Federal Register the Office of Energy Research Financial Assistance Program (now called the Office of Science Financial Assistance Program), 10 CFR 605, as a Final Rule, which contained a solicitation for this program. Information about submission of applications, eligibility, limitations, evaluation and selection processes and other policies and procedures are specified in 10 CFR 605. This NOFO is our annual open solicitation that covers all research areas in SC and is open throughout the Fiscal Year. Any research within SC’s Congressionally authorized mission may be proposed under this NOFO. This NOFO will remain open until September 30, 2026, 11:59 PM Eastern Time, or until it is succeeded by another issuance, whichever occurs first. This NOFO succeeds DE-FOA-0003432, which was published September 30, 2024.
FY 2024 – 2026 Broad Agency Announcement (BAA), National Marine Fisheries Service
Due Sep 30, 2026DOC NOAA - ERA Production · $0
This BAA is for the National Marine Fisheries Service, also known as NOAA Fisheries. The purpose of this notice is to request applications for special projects and programs associated with the NOAA Fisheries strategic plan and mission goals, as well as to provide the general public with information and guidelines on how NOAA will select applications and administer discretionary Federal assistance under this Broad Agency Announcement (BAA). This notice is not a mechanism to fund existing NOAA awards. Each NOAA Line Office that supports financial assistance (National Marine Fisheries Service, National Ocean Service, National Weather Service, Office of Atmospheric Research, Office of Education, and National Environmental Satellite Data Information Service) has a separate BAA found in Grants.gov, so applicants should submit their application to the BAA for the Line Office that best fits their application. A description of NOAA Line Offices is found at https://www.corporateservices.noaa.gov/public/lineoffices.html and https://www.noaa.gov/office-education. Applicants may also contact the Agency Contact below for more information. If you submit the same application to more than Line Office, mention this in your application and notify the relevant contacts so that NOAA may coordinate internally.
GEOSPATIAL INTELLIGENCE PROCESSING AND EXPLOITATION (GeoPEX)
Due Sep 30, 2026Air Force -- Research Lab · Up to $99.9M
PLEASE NOTE: No submissions through Grants.gov will be accepted. All submissions must follow SAM.gov instructions. For full opportunity announcement reference the SAM.gov link.
FY 2024 – 2026 - Broad Agency Announcement (BAA) for the Office of Education
Due Sep 30, 2026DOC NOAA - ERA Production · $0
This notice is not a mechanism to fund existing NOAA awards. The purpose of this notice is to request applications for special projects and programs associated with NOAA's strategic plan and mission goals, as well as to provide the general public with information and guidelines on how NOAA will select applications and administer discretionary Federal assistance under this Broad Agency Announcement (BAA). Each NOAA Line or Staff Office that supports financial assistance (National Marine Fisheries Service, National Ocean Service, National Weather Service, Office of Atmospheric Research, Office of Education, and National Environmental Satellite Data Information Service) has a separate BAA found in Grants.gov, so applicants should submit their application to the BAA for the Line Office that best fits their application. A description of NOAA Line Offices is found at https://www.corporateservices.noaa.gov/public/lineoffices.html and https://www.noaa.gov/office-education, and applicants may contact the Agency Contacts in Section VII. below for more information. If you submit the same application to more than Line Office, mention this in your application and notify the relevant contacts in Section VII. so that NOAA may coordinate internally.
DoW, Ovarian Cancer, Pilot Award
Due Oct 1, 2026Defense Health Agency Contracting Activity - DHACA · Amount varies
Summary: The Ovarian Cancer Pilot Award supports research that expands or modifies current thinking about and/or approaches in ovarian cancer, exploring innovative concepts or theories in ovarian cancer that could ultimately lead to critical discoveries or major advancements that will drive the field forward. Distinctive Features: Innovation is key. Research projects that demonstrate exceptional scientific merit but lack innovation do not meet the intent of the mechanism. Preliminary data are not required but are allowed for this mechanism. This mechanism includes a blinded pre-application component. Pre-applications to this funding opportunity will undergo a blinded pre-application screening. While preparing your pre-application, do not include any material that may identify the PI, a collaborator, or the organization of the PI or collaborator.
DoW Ovarian Cancer, Clinical Trial Award
Due Oct 1, 2026Defense Health Agency Contracting Activity - DHACA · Amount varies
Summary: The OCRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ovarian cancer. Distinctive Features: Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.
DoW, Ovarian Cancer, Investigator-Initiated Research Award
Due Oct 1, 2026Defense Health Agency Contracting Activity - DHACA · Amount varies
Summary: The Ovarian Cancer Research Program (OCRP) Investigator-Initiated Research Award is intended to support high-impact research that addresses a critical need and has the potential to make an important contribution to ovarian cancer or patient/survivor care. Distinctive Features: Application must contain strong research plan with sound scientific rational and logical reasoning. Preliminary data are required. Research projects may focus on any phase of research, from basic laboratory research through translational research, excluding clinical trials. Partnering Principal Investigator (PI) Option: The Partnering PI Option is structured so that two investigators, each of whom will be designated as a PI, will work synergistically on a single project. The results of this partnering project should significantly advance the research beyond what would be possible through individual efforts.
DoW, Ovarian Cancer, Ovarian Cancer Academy – Early-Career Investigator Award
Due Oct 1, 2026Defense Health Agency Contracting Activity - DHACA · Amount varies
Summary: Initially created in FY09, the OCRP Ovarian Cancer Academy (OCA) is a unique, interactive virtual academy providing intensive mentoring, national networking, collaborations, and a peer group for junior faculty. The overarching goal of the OCA is to conduct innovative and impactful ovarian cancer research while developing successful, highly productive ovarian cancer researchers in a collaborative research and career development environment. Distinctive Features: The OCA is a virtual career development and research training platform that consists of Early-Career Investigators (ECIs), their Designated Mentors, and an Academy Dean and Assistant Dean. The OCA-ECI Award is not a traditional career development award; the ECI is expected to participate in monthly webinars and annual workshops and to communicate and collaborate with other members of the Academy (other ECIs, Mentors, the Dean and Assistant Dean) as well as with the advocacy community.
DoW, Ovarian Cancer, Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award
Due Oct 1, 2026Defense Health Agency Contracting Activity - DHACA · Amount varies
Summary: Created in FY23, the Ovarian Cancer Clinical Trial Academy (OCCTA) supports the next generation of Early-Career Investigators (ECIs) in clinical trial research to produce effective treatments and cures for ovarian cancer. The OCCTA, through its Leadership, provides for professional and leadership development of the ECIs to include skills and competencies needed to execute clinical trials, providing intensive mentoring, national networking, collaborations, and a peer group for junior clinical trialists. The OCCTA will bring together established investigators (the Academy Dean and Assistant Dean), established Career Guides (mentors), and a group of ECIs/Scholars to conduct successful, highly productive clinical trials in ovarian cancer. Distinctive Features: Research funded under this FY26 funding opportunity will support translational research and small-scale, early-phase clinical trials in ovarian cancer. Preliminary data are required, however, these data do not necessarily need to be derived from the ovarian cancer research field. The ECI must be within 12 years of their last postdoctoral research position (Ph.D.), clinical fellowship (M.D.), or equivalent at the time of full application submission deadline. The ECI must commit no less than 25% effort to this award and/or OCCTA activities for the first two years. The Designated Mentor must be a clinical trialist with a strong record of mentoring and training early-career investigators.
EDU Core Research
Due Oct 1, 2026U.S. National Science Foundation · $500K–$2.5M
The EDU Core Research (ECR) program offers this ECR:Core solicitation and invites proposals for fundamental research (curiosity-driven basic research and use-inspired basic research) that contributes to the general, explanatory knowledge that underlies STEM education in one or more of the three broadly conceived Research Areas: Research onSTEM Learning and Learning Environments, Research on Broadening Participation in STEM fields, andResearch on STEM Workforce Development. Within this framework, the ECR program supports a wide range of fundamental STEM education research activities, aimed at learners of all groups and ages in formal and informal settings. Fundamental researchgenerates knowledge and understanding with the potential for broad relevance. The potential implications of ECR fundamental research for improving STEM education practice may be indirect and long-term rather than direct and immediate. Moreover, whether they include basic or use-inspired basic research, all successful ECR:Core proposals focus on the advancement or refinement of foundational knowledge for STEM education. The amount of funding and duration requested in proposals submitted to the ECR:Core solicitation should align with the maturity of the proposed work and the size and scope of the empirical effort. The solicitation has three levels of funding with a range of budget sizes, and proposals may request a duration of 3 to 5 years for any level: (1)Level I proposals may request up to $500,000; (2)Level II proposals may request up to $1,500,000; (3)Level III proposalsmay request up to $2,500,000. All proposals should justify the level of funding and duration in the project description.